Rare Disease Company Coalition
Companies committed to discovering, developing, & delivering rare disease treatment
Based in DC
🤖
AI Overview
With $1.1M in lobbying spend across 17 quarterly filings, Rare Disease Company Coalition is a significant lobbying presence. Their lobbying covers 3 issue areas. Active from 2021 to 2024.
$1.1M
Total Spend
4
Years Active
1
Firms Hired
8
Lobbyists Deployed
3
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $120K |
| 2022 | $180K |
| 2023 | $240K |
| 2024 | $560K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Pharmacy, Medicare/Medicaid
- •Treatment of rare diseases.
- •Senate Finance Committee Drug Pricing Principles
- •Medicare Negotiation
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.